ReviewFuture oncology (London, England)2025
Pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.
Review in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- FDA-Approved Drugs Containing Amide Functionality in the Last Five Years (2021-2025): Pharmaceutical Use, Trends and Synthetic Approaches.Medicines (Basel, Switzerland) · 2026Review
- Non-receptor tyrosine kinase signaling pathways and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody-Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat.Journal of clinical medicine · 2026Review
- UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies.Journal of hematology & oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pirtobrutinib, a novel noncovalent Bruton's tyrosine kinase (BTK) inhibitor (BTKi) has demonstrated significant potential in overcoming treatment resistance characterized by BTK mutations in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL). Unlike currently approved covalent BTKi (cBTKi) such as ibrutinib, acalabrutinib, and zanubrutinib that irreversibly bind to the cysteine 481 (C481) residue of BTK, pirtobrutinib's non-covalent binding enables it to maintain efficacy even in the presence of cysteine 481 serine (C481S) mutations which are the most common form of acquired resistance. This current review seeks to demonstrate the mechanism of action as well as the clinical efficacy of pirtobrutinib in treating patients with relapsed/refractory CLL/SLL and to describe ongoing studies of pirtobrutinib in combination with other agents and in earlier lines of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.